Inocras, Samsung Medical Center and Seoul St. Mary’s Hospital Researchers Publish Groundbreaking Study with 1,364 Whole-Genomes of Breast Cancer in Nature

Landmark study from Inocras, Samsung Medical Center and Seoul St. Mary’s Hospital Researchers explores the whole genomes of 1,364 breast cancers, uncovering predictive biomarkers that link genomic signatures to potential treatment outcomes and support advancing precision oncology.

Lab Thread Announces Beta Release of Unified Lab Software Platform

Silverstone, UK, 8 December 2025: Lab Thread Ltd, a UK‐based life science software company, today announced the beta launch of its flagship unified lab software platform. Lab Thread is uniquely designed to provide an intuitive and adoptable platform with powerful collaborative features – helping to unite researchers, lab operations and scientific data from across diverse teams and advance scientific discovery.

Quotient Sciences and Intrepid Labs form strategic partnership to accelerate AI-guided formulation development

Vaxess Human Factors Study Shows Patient Preference for Patch-Based GLP-1 Delivery Over Injections

Company’s third Human Factors Formative Study shows that 95% of participants prefer the Vaxess microarray patch to traditional injection devices

Groundbreaking myalgic encephalomyelitis study identifies over 250 core genes, shared biology with long COVID, and dozens of drug repurposing opportunities

PrecisionLife has announced new findings from the most detailed genetic analysis of myalgic encephalomyelitis ever conducted offering potential for faster and lower-risk routes to developing targeted treatments.

4D Path’s Physics-Inspired QPOR™ Platform Predicts Neoadjuvant Chemotherapy Response from Routine Biopsy Images in Early-Stage Triple-Negative Breast Cancer from Phase II TBCRC-030 Trial

4D Path, a company dedicated to personalizing cancer care through a novel, physics-inspired approach to predicting tumor response to therapy, today announced that the company’s Q-Plasia OncoReader (QPOR™) platform has successfully predicted treatment response in patients with early-stage triple-negative breast cancer (TNBC) using digitized baseline biopsy images. Analysis conducted within the Translational Breast Cancer Research Consortium (TBCRC) 030 clinical trial represents the first demonstration of a statistical physics and tumor biology-based computational biomarker predicting post-treatment outcomes from pre-treatment tissue alone, without any clinical or molecular inputs.

Proscia Achieves SOC 2 Type II Certification, Strengthening Enterprise Trust

Compliance with independent security standards comes as Proscia accelerates digital pathology deployments at scale

Bioscript Group launches new AI-augmented platform helping medical affairs teams transform data into action

Symbiosis Formally Presented with Prestigious King’s Award by Lord Lieutenant of Stirling and Falkirk

Biocair France Relocates to Strategic New Facility at Paris-Charles de Gaulle Airport

Biocair, an established global leader in life science logistics, today announced the relocation of its Paris facility to a new, substantially larger premises strategically positioned within the Paris-Charles de Gaulle airport cargo zone.

TeleTracking Launches First AI-Powered Patient Throughput Solution, Decision IQ®

Symbiosis Builds Global Business Development Strength with Two North American Appointments

Nanopath Granted FDA Breakthrough Device Designation for Its Molecular Diagnostic Platform for Urinary Tract Infections

Nanopath, a point-of-care diagnostics company enabling high-quality molecular testing in minutes, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation for the company's novel assay for the rapid detection of infection in patients with suspected, or at risk of, complicated urinary tract infections (UTIs).

Verista Sets New Standard for Commissioning, Qualification, and Validation Services in Medical Device Manufacturing

Accelerating medical device validation with digital solutions, risk-based methodology, and proven regulatory expertise.

Zymo Research Announces Strategic Partnership with biomodal to Deliver Next-Gen Multiomic Insights

Zymo Research, a global leader in epigenetics and next-generation sequencing (NGS), has entered a strategic partnership with biomodal, an omics-based life sciences technology and analytics company. As part of biomodal’s certified provider network, Zymo Research’s NGS Services division is now authorized to deliver services using biomodal’s duet multiomics solution evoC and duet multiomics solution +modC, enabling researchers to access comprehensive genetic and epigenetic insights from a single DNA sample.

BioGrad Leads £6 Million Worth PCR Machine Donation to Strengthen UK Science Education

BioGrad is spearheading efforts to place £10.5 million worth of donated PCR equipment by the end of 2025, with £6 million already delivered across the UK.

ThirdLaw Molecular Rebrands as Ladder Bio; Announces $5.5M Seed Financing Led by Medical Excellence Capital and Appoints Eric Heil as Chief Executive Officer

ThirdLaw Molecular, Inc. today announced its new name change, Ladder Bio Inc., reflecting the company’s mission to pioneer Spiroligomer™ therapeutics (“ladder-shaped peptide-like molecules”), a novel therapeutic modality for new medicines. The company name change follows the closing of a $5.5 million Series Seed financing led by Medical Excellence Capital, with participation from Hatch BioFund. The company also announced the appointment of Eric Heil as Chief Executive Officer and the election of David Scheer and Brian Halak, PhD to its Board of Directors.

Advarra and IgniteData announce partnership to simplify clinical trial data transfer for research sites

IgniteData’s Archer platform will connect the site’s EHR system, Advarra’s eSource and EDC systems, and the sponsor’s EDC system of choice, ensuring compatibility between solutions from different vendors.

Integrated DNA Technologies and Beckman Coulter Life Sciences Partner to Advance Cancer Research Through Automated NGS Workflows

Collaboration aims to equip users with complete NGS solution from sample to answer

CluePoints Data and Knowledge Manager Appointed to ACT Editorial Advisory Board

CluePoints, provider of leading statistical and AI-driven software solutions, has announced Sylviane de Viron, its Data and Knowledge Manager, has been appointed to the Applied Clinical Trials (ACT) editorial advisory board.